{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:46:24Z","timestamp":1793303184792,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>In patients with clinically node-negative (cN0) breast cancer and 1 or 2 sentinel lymph node (SLN) macrometastases, omitting completion axillary lymph node dissection (CALND) is standard. High nodal burden (\u22654 axillary nodal metastases) is an indication for intensified treatment in luminal breast cancer; hence, abstaining from CALND may result in undertreatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To develop a prediction model for high nodal burden in luminal\n                      <jats:italic>ERBB2<\/jats:italic>\n                      -negative breast cancer (all histologic types and lobular breast cancer separately) without CALND.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>\n                      The prospective Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases (SENOMAC) trial randomized patients 1:1 to CALND or its omission from January 2015 to December 2021 among adult patients with cN0 T1-T3 breast cancer and 1 or 2 SLN macrometastases across 5 European countries. The cohort was randomly split into training (80%) and test (20%) sets, with equal proportions of high nodal burden. Prediction models were developed by multivariable logistic regression in the complete luminal\n                      <jats:italic>ERBB2<\/jats:italic>\n                      -negative cohort and a lobular breast cancer subgroup. Nomograms were constructed. The present diagnostic\/prognostic study presents the results of a prespecified secondary analysis of the SENOMAC trial. Herein, only patients with luminal\n                      <jats:italic>ERBB2<\/jats:italic>\n                      -negative tumors assigned to CALND were selected. Data analysis for this article took place from June 2023 to April 2024.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Predictors of high nodal burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>High nodal burden was defined as \u22654 axillary nodal metastases. The luminal prediction model was evaluated regarding discrimination and calibration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1010 patients (median [range] age, 61 [34-90] years; 1006 [99.6%] female and 4 [0.4%] male), 138 (13.7%) had a high nodal burden and 212 (21.0%) had lobular breast cancer. The model in the training set (n\u2009=\u2009804) included number of SLN macrometastases, presence of SLN micrometastases, SLN ratio, presence of SLN extracapsular extension, and tumor size (not included in lobular subgroup). Upon validation in the test set (n\u2009=\u2009201), the area under the receiver operating characteristic curve (AUC) was 0.74 (95% CI, 0.62-0.85) and the calibration was satisfactory. At a sensitivity threshold of \u226580%, all but 5 low-risk patients were correctly classified corresponding to a negative predictive value of 94%. The prediction model for the lobular subgroup reached an AUC of 0.74 (95% CI, 0.66-0.83).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The predictive models and nomograms may facilitate systemic treatment decisions without exposing patients to the risk of arm morbidity due to CALND. External validation is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02240472\">NCT02240472<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamasurg.2024.3944","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T17:39:45Z","timestamp":1727285985000},"page":"1393","source":"Crossref","is-referenced-by-count":16,"title":["Prediction of High Nodal Burden in Patients With Sentinel Node\u2013Positive Luminal\n                    <i>ERBB2<\/i>\n                    -Negative Breast Cancer"],"prefix":"10.1001","volume":"159","author":[{"given":"Ida","family":"Skarping","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden"},{"name":"Department of Clinical Physiology and Nuclear Medicine, Skane University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r-Ola","family":"Bendahl","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Szulkin","sequence":"additional","affiliation":[{"name":"Cytel Inc, Sweden"},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Alkner","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden"},{"name":"Department of Hematology, Oncology and Radiation Physics, Skane University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Andersson","sequence":"additional","affiliation":[{"name":"Department of Surgery, V\u00e4stmanland Hospital, V\u00e4ster\u00e5s, Sweden"},{"name":"Centre for Clinical Research Uppsala University, V\u00e4stmanland Hospital V\u00e4ster\u00e5s, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Bergkvist","sequence":"additional","affiliation":[{"name":"Centre for Clinical Research Uppsala University, V\u00e4stmanland Hospital V\u00e4ster\u00e5s, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peer","family":"Christiansen","sequence":"additional","affiliation":[{"name":"Department of Plastic and Breast Surgery, Aarhus University Hosoital, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Filtenborg Tvedskov","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Gentofte Hospital, Denmark"},{"name":"Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Frisell","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden"},{"name":"Breast Center Karolinska, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreste D.","family":"Gentilini","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Vita-Salute San Raffaele, Milano, Italy"},{"name":"IRCCS Ospedale San Raffaele, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalis","family":"Kontos","sequence":"additional","affiliation":[{"name":"1st Department of Surgery, National and Kapodistrian University of Athens, Laiko Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"K\u00fchn","sequence":"additional","affiliation":[{"name":"Interdisciplinary Breast Center, University of Ulm, Ulm, Germany"},{"name":"Breast Center Die Filderklinik, Filderstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Lundstedt","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Vrou Offersen","sequence":"additional","affiliation":[{"name":"Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Oncology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Aarhus University, Faculty of Health, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[{"name":"Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden"},{"name":"Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toralf","family":"Reimer","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Rostock, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Sund","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Department of Diagnostics and Intervention\/Surgery, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ryd\u00e9n","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden"},{"name":"Department of Surgery and Gastroenterology, Skane University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"de Boniface","sequence":"additional","affiliation":[{"name":"Department of Surgery, Capio St G\u00f6ran\u2019s Hospital, Stockholm, Sweden"},{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"soi240070r1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial.","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"soi240070r2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","article-title":"Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.","volume":"14","author":"Galimberti","year":"2013","journal-title":"Lancet Oncol"},{"issue":"12","key":"soi240070r3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"soi240070r4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","article-title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.","volume":"30","author":"Burstein","year":"2019","journal-title":"Ann Oncol"},{"issue":"34","key":"soi240070r5","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (MONARCHE).","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"soi240070r6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01994","article-title":"Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned MONARCHE overall survival interim analysis, including 5-year efficacy outcomes.","volume":"42","author":"Rastogi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"soi240070r7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer.","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"soi240070r8","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"soi240070r9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-005-9025-7","article-title":"Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer.","volume":"95","author":"Fleissig","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"soi240070r10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.breast.2022.02.013","article-title":"Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial.","volume":"63","author":"Appelgren","year":"2022","journal-title":"Breast"},{"issue":"3","key":"soi240070r11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1148\/radiol.2020192534","article-title":"Axillary nodal evaluation in breast cancer: state of the art.","volume":"295","author":"Chang","year":"2020","journal-title":"Radiology"},{"issue":"4","key":"soi240070r12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ejso.2011.01.006","article-title":"Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive SLN.","volume":"37","author":"van la Parra","year":"2011","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"soi240070r13","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1002\/onco.13734","article-title":"Comprehensive review of molecular mechanisms and clinical features of invasive lobular cancer.","volume":"26","author":"Pramod","year":"2021","journal-title":"Oncologist"},{"issue":"8","key":"soi240070r14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.annonc.2022.05.006","article-title":"Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.","volume":"33","author":"Van Baelen","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"soi240070r15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13058-015-0519-x","article-title":"Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics.","volume":"17","author":"McCart Reed","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"1","key":"soi240070r16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13058-020-01384-6","article-title":"Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.","volume":"23","author":"McCart Reed","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"12","key":"soi240070r17","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1093\/bjs\/znab327","article-title":"St Gallen 2019 guidelines understage the axilla in lobular breast cancer: a population-based study.","volume":"108","author":"Narbe","year":"2021","journal-title":"Br J Surg"},{"issue":"5","key":"soi240070r18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s12282-018-0852-x","article-title":"Comparison of sentinel lymph node biopsy between invasive lobular carcinoma and invasive ductal carcinoma.","volume":"25","author":"Adachi","year":"2018","journal-title":"Breast Cancer"},{"issue":"11","key":"soi240070r19","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1245\/s10434-014-3813-4","article-title":"Predicting the extent of nodal disease in early-stage breast cancer.","volume":"21","author":"Caudle","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"soi240070r20","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/bjs.10791","article-title":"Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast.","volume":"105","author":"Morrow","year":"2018","journal-title":"Br J Surg"},{"issue":"7","key":"soi240070r21","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.ejso.2014.03.026","article-title":"The sensitivity of pre-operative axillary staging in breast cancer: comparison of invasive lobular and ductal carcinoma.","volume":"40","author":"Topps","year":"2014","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"soi240070r22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/tbj.12042","article-title":"Influence of tumor histology on preoperative staging accuracy of breast metastases to the axilla.","volume":"19","author":"Hackney","year":"2013","journal-title":"Breast J"},{"issue":"15","key":"soi240070r23","doi-asserted-by":"publisher","first-page":"e12604","DOI":"10.1200\/JCO.2020.38.15_suppl.e12604","article-title":"Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast.","volume":"38","author":"Guo","year":"2020","journal-title":"J Clin Oncol"},{"key":"soi240070r24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.breast.2020.08.001","article-title":"Development and external validation of a nomogram to predict four or more positive nodes in breast cancer patients with one to three positive sentinel lymph nodes.","volume":"53","author":"Yang","year":"2020","journal-title":"Breast"},{"issue":"1","key":"soi240070r25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12957-022-02779-9","article-title":"Development and validation of a pre- and intra-operative scoring system that distinguishes between non-advanced and advanced axillary lymph node metastasis in breast cancer with positive sentinel lymph nodes: a retrospective study.","volume":"20","author":"Murata","year":"2022","journal-title":"World J Surg Oncol"},{"issue":"3","key":"soi240070r26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4048\/jbc.2017.20.3.270","article-title":"Development of a nomogram to predict N2 or N3 stage in T1-2 invasive breast cancer patients with no palpable lymphadenopathy.","volume":"20","author":"Kim","year":"2017","journal-title":"J Breast Cancer"},{"issue":"35","key":"soi240070r27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021721","article-title":"Prediction of nodal staging in breast cancer patients with 1-2 sentinel nodes in the Z0011 era.","volume":"99","author":"Corsi","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"soi240070r28","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s10549-013-2468-3","article-title":"International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases.","volume":"138","author":"Meretoja","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"soi240070r29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12885-017-3361-y","article-title":"Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.","volume":"17","author":"de Boniface","year":"2017","journal-title":"BMC Cancer"},{"issue":"13","key":"soi240070r30","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","article-title":"Omitting axillary dissection in breast cancer with sentinel-node metastases.","volume":"390","author":"de Boniface","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"soi240070r32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/his.12869","article-title":"E-cadherin immunohistochemistry in breast pathology: uses and pitfalls.","volume":"68","author":"Canas-Marques","year":"2016","journal-title":"Histopathology"},{"issue":"24","key":"soi240070r33","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated Standardized Definitions for Efficacy End Points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0.","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"soi240070r34","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","article-title":"Eight-year follow up result of the OTOASOR trial: the Optimal Treatment of the Axilla\u2014Surgery or Radiotherapy After Positive Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: a randomized, single centre, phase III, non-inferiority trial.","volume":"43","author":"S\u00e1volt","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"soi240070r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.107954","article-title":"Is routine axillary lymph node dissection needed to tailor systemic treatments for breast cancer patients in the era of molecular oncology? a position paper of the Italian National Association of Breast Surgeons (ANISC).","volume":"50","author":"Rocco","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"soi240070r36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1245\/s10434-022-12203-x","article-title":"Axillary staging is not justified in postmenopausal clinically node-negative women based on nodal disease burden.","volume":"30","author":"Lee","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"soi240070r37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10549-022-06572-w","article-title":"Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.","volume":"193","author":"Mouabbi","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"soi240070r38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1245\/ASO.2006.03.080","article-title":"Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node.","volume":"13","author":"Rivers","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"soi240070r39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1148\/radiol.10100296","article-title":"Can preoperative axillary US help exclude N2 and N3 metastatic breast cancer?","volume":"257","author":"Neal","year":"2010","journal-title":"Radiology"},{"issue":"3","key":"soi240070r40","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10549-023-07044-5","article-title":"Clinical characteristics and treatment outcomes of invasive ductal and lobular carcinoma: analyses of 54,832 Taiwan cancer registry index cases.","volume":"201","author":"Chen","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"soi240070r41","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jnci\/djac157","article-title":"Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer.","volume":"114","author":"Oesterreich","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"soi240070r42","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s12282-023-01457-2","article-title":"High-accuracy prediction of axillary lymph node metastasis in invasive lobular carcinoma using focal cortical thickening on magnetic resonance imaging.","volume":"30","author":"Kawaguchi","year":"2023","journal-title":"Breast Cancer"},{"issue":"5","key":"soi240070r43","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3390\/biomedicines11051350","article-title":"FDG and Non-FDG radiopharmaceuticals for PET imaging in invasive lobular breast carcinoma.","volume":"11","author":"Gilardi","year":"2023","journal-title":"Biomedicines"},{"issue":"3","key":"soi240070r44","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10549-020-06047-w","article-title":"Is axillary imaging for invasive lobular carcinoma accurate in determining clinical node staging?","volume":"185","author":"Schumacher","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"25","key":"soi240070r45","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"soi240070r46","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/jbi\/wbab070","article-title":"Axillary ultrasound evaluation in breast cancer patients: a multidisciplinary viewpoint and middle ground.","volume":"3","author":"Saksena","year":"2021","journal-title":"J Breast Imaging"},{"key":"soi240070r31","volume-title":"TNM Classification of Malignant Tumours","author":"Sobin","year":"2009"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2824187\/jamasurgery_skarping_2024_oi_240070_1783977019.58296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:00:51Z","timestamp":1784127651000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2824187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2024.3944","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}